← Two worlds

Sources and credits.

This website presents Yashasvee Chandra’s MSc thesis, Governance at the Threshold, and the author’s account of making it. The research follows companies to 25 September 2026; the author reports locking the data on 16 October 2026.

Which checking figures belong together?

I hand-checked 160 boards, including 120 blind (without seeing their later outcomes). The random blind check covered 100 boards and 689 seats; the final thesis reports 98.5% agreement, with kappa 0.968.

The first blind check covered 20 boards and 145 seats (kappa 0.94). The earlier non-blind check covered 40 boards and agreed on 283 of 287 seats (98.6%; kappa 0.971). The final thesis separately reports 98.5% across 689 seats in the 100-board blind check (679 of 689; kappa 0.968). These are source-reported checks, not an independent verification by this website.

Final sources: Thesis, pages 46 and 47, and Annex C, pages C-16 and C-17.

The separate AI re-coding covered 450 boards in the earlier frame. Of these, 448 remained in the final frame; four later additions were coded separately, producing the final 452-company frame. These are different stages of a check.

Reading the evidence

Most measured values are rounded to one decimal. P-values retain source precision, with scientific notation for small values. The original figures and source text retain their printed values. The website communicates the supplied research; it has not independently re-fitted its models or verified the author’s review records.

Two AI reviews of the author’s analysis reported matching model results. They are AI-assisted checks, not an official examination or independent human review.

About the author ↗︎

Additional explanatory sources

The introductory explanation of IPO allocations uses the SEC’s investor bulletin. CoLucid’s acquisition context uses Lilly’s 1 March 2017 announcement. These explain market mechanics and the buyer’s stated rationale; they do not verify the thesis’s causal interpretation.

Research and design

Author: Yashasvee Chandra. Supervisor: Julie Rachline (LallianSe website ↗︎ · Julie’s LinkedIn ↗︎). School: ESCP Business School. The Footnotes illustrations, lab instruments and decorative charts were created for this website as storytelling devices. Research figures and tables come from the supplied thesis and annexes; the relevant chapters retain their source references.

Read the personal acknowledgements in People behind the research.

THE PICTURES BEHIND THE RESEARCH

Artwork and permissions.

Illustrations created and supplied by Yashasvee Chandra for this website.

The Footnotes illustrations, instruments and decorative charts were created for the website as storytelling devices. Research figures and tables come from the supplied thesis and annexes.

ABOUT THE RESEARCH

Frequently asked questions

Why study companies that listed between 2015 and 2021?

This period provides a sizeable group of biotech listings, with several years to observe what happened afterwards. The frame has 452 companies: 349 in North America and 103 in Europe. The listing window ends in 2021; outcomes are followed through 25 September 2026.

Why use SEC filings?

They are public documents that name directors, major shareholders and the connections between them. The ownership footnotes help establish which investor a director represents. SEC filings cover the US-listed companies; European home-listed companies required other sources.

Why study listed companies rather than private ones?

The question concerns what happens after an IPO. Listing provides a common starting point and detailed disclosures. Private companies, and companies acquired before completing an IPO, fall outside this study.

Read all 24 questions